**Adhesion Prevention Strategies in Laparoscopic Surgery**

George Pados, Anastasios Makedos and Basil Tarlatzis

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/52694

### **1. Introduction**

[31] Lee JH, Huh J, Kim DK, et al. Laparoscopic cholecystectomy under epidural anesthe‐ sia: a clinical feasibility study. Korean Journal of Anesthesiology 2010; 59(6): 383-388.

[32] Joshi GP. Complications of laparoscopy. Anesthesiology Clinic of North America

[33] Amornyotin S, Chalayonnawin W, Kongphlay S. A randomized controlled trial of preprocedure administration of parecoxib for therapeutic endoscopic retrograde

[34] Fujii Y. Management of postoperative nausea and vomiting in patients undergoing

[35] Wu SJ, Xiong XZ, Cheng TY, Lin YX, Cheng NS. Efficacy of ondansetronvs metoclo‐ pramide in prophylaxis of postoperative nausea and vomiting after laparoscopic cholecystectomy: a systematic review and meta-analysis. Hepatogastroenterology

cholangiopancreatography. Journal of Pain Research 2012; 5: 251-256.

laparoscopic cholecystectomy. Surgical Endoscopy 2011; 25(3): 691-695.

2012; 59(119), Doi: 10.5754/hge11811 [Epub ahead of print]

2001; 19(1): 89-105.[33]

48 Endoscopy

Adhesions are defined as abnormal attachments between tissues and organs [1]. Intra-ab‐ dominal adhesions may be classified as congenital or acquired [2]. Congenital adhesions are a consequence of embryological anomaly in the development of the peritoneal cavity. Ac‐ quired adhesions result from the inflammatory response of the peritoneum that arises after intra-abdominal inflammatory processes (e.g. acute appendicitis, pelvic inflammatory dis‐ ease, exposure to intestinal contents and previous use of intrauterine contraceptive devices), radiation and surgical trauma [3]. It has been reported that the majority of acquired adhe‐ sions (about 90%) are post-surgical [2].

Factors associated with the formation of post-surgical adhesions include tissue trauma, in‐ fection, ischaemia,reaction to foreign bodies (sutures, powder from gloves, gauze particles etc.), haemorrhage, tissue overheating or desiccation and exposure to irrigation fluids [4]. The incidence of intra-abdominal adhesions ranges from 67% to 93% after general surgical abdominal operations and from 60% to 90% after gynecological procedures. Not unexpect‐ edly, adhesion formation is considered one of the most common post-operative complica‐ tions [2,5]. Post-surgically, many adhesions may be asymptomatic or can lead to a broad spectrum of clinical problems, including intestinal obstruction, chronic pelvic or abdominal pain and female infertility, requiring re-admission and often additional surgery, while at the same time they can complicate future surgical procedures [6]. Adhesion-related re-opera‐ tions are a common consequence of gynecological procedures and adhesiolysis is followed by a high incidence of adhesion reformation and *de-novo* adhesion formation [7].

The major strategies for adhesion prevention in gynecological surgery aim at the optimiza‐ tion of surgical technique and use of adhesion-prevention agents. Laparoscopic surgery in

© 2013 Pados et al.; licensee InTech. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. © 2013 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

gynecology represents the most innovative surgical approach, compared with laparotomy since it has been shown from a large number of clinical, but also experimental studies, that is associated with less development of *de novo* adhesions. Without any doubt, the most im‐ portant factor is the operating surgeon, whose attention to proper surgical technique will serve as a mainstay for adhesion formation.

The deposition is the key step for the healing process and the balance between deposition and degradation will determine normal peritoneal healing or adhesion formation. The fibrin absorption is controlled by fibrinolysis. The inactive plasminogen is converted to plasmin through tissue plasminogen activator (tPA) and urokinase type plasminogen activator (uPA). The tPA is present in both mesothelium and submesothelial blood vessels of serosal and peritoneal membranes[12,15]. The fibrinolytic activity normally begins three days after peritoneal injury and increases to a maximum by day 8. Therefore, those adhesions that will be formed are in place by day 8, when mesothelial regeneration has been completed [8]. Normal peritoneum has a high fibrolytic activity in order to prevent adhesion formation be‐ tween different tissue surfaces. During the inflammatory process, IL-1 and IL-6 stimulate epithelial and inflammatory cells to release plasminogen activator inhibitor 1 and 2 (PAI-1 and PAI-2), which inhibit fibrinolytic activity [16]. Patients with extensive adhesions have been found to have an overexpression of PAI-1 in the peritoneum [17]. Also, the deficient blood supply, the reduced tissue oxygenation and the release of reactive oxygen species that frequently co-exist with surgical trauma, decrease the peritoneal fibrinolytic activity [9,18].

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

51

In order to prevent the development and reformation of post-operative intra-abdominal adhe‐ sions a variety of surgical techniques and adjuvants have been proposed. Agents, that in theory can modify the mechanism of adhesion formation, have been evaluated in experimental trials and many of them have been advocated for use during surgery in humans. Surgical techniques are focused on the limitation of surgical trauma, prevention of ischaemia and exposure of peri‐ toneal cavity to foreign materials (Table 1). Improvement of surgical techniques can potentially reduce adhesion formation but cannot eliminate it. Anti-adhesive agents can be classified as pharmacological agents, systemic or intra-peritoneal, and intra-peritoneal barriers (solid or liquid). Pharmacological agents (Table 2) target the modification of inflammatory reaction (limitation of fibrin deposition), amplification of fibrin absorption and suppression of fibro‐ blast activity. Barriers (Table 3) are used in order to prevent traumatized peritoneal surface ap‐

position during the healing process so as to prevent tissue adherence [17,19].

**3. Adhesion prevention**

Achieving excellent haemostasis and avoiding

Avoiding foreign bodies (talc, starch) Avoiding peritoneum suturing or use of fine

Reducing drying or overheating of tissues

Removing intra-peritoneal blood deposits

**Table 1.** Surgical techniques for prevention of adhesion formation

local ischaemia

non-reactive suture Minimizing surgical trauma Minimizing tissue handling

Reducing infection risk

### **2. Mechanism of adhesion development**

The mechanism of adhesion formation represents a variation of the physiological healing process [8]. The process of peritoneal healing differs from that of other tissues. Peritoneal defects heal by a process of metaplasia from the underlying mesenchyme, partly from mi‐ gration of epithelial cells from the free peritoneal fluid and minimally through proliferation of epithelial cells from the defect's edges. Consequently, peritoneal wounds need the same time to heal regardless of their size, in contrast with other tissues, such as the skin, where large injuries take longer to heal than do small injuries [9]. There is no difference between peritoneal healing and adhesion formation for the first 3 days after peritoneal injury. Injuries to the peritoneum cause a disruption of stromal mast cells, resulting in the release of hista‐ mine and vasoactive cinins. Also as a response to trauma, various cytokines, such as inter‐ leukin (IL)-1, IL-6 and tumor necrosis factor-a (TNF-a) are locally released. The cytokines attract and activate macrophages to secrete vasodilating substances, which in turn, cause an increase in capillary permeability, leading to the formation of fibrous exudate [10]. Platelets are an important component of the inflammatory exudate and have the ability to adhere it to the traumatized surfaces. The platelet degranulation releases adrenaline, transforming growth factor b and serotonin and contribute to the production of prostaglandins and leuko‐ trienes. The chemokines direct the migration of cells to the injury site, while platelets con‐ tribute to the initial fibrin clot and to the initiation of the coagulation process [11]. The activation of the coagulation cascade leads to the transformation of the inactive prothrombin into thrombin that triggers the conversion of fibrinogen into monomers of fibrin, which in‐ teract and polymerize. The initially soluble polymer becomes insoluble by coagulation fac‐ tors such as factor XIIIa [12]. The exudate coagulates within 3 h and forms a fibrinous material that plugs the defective area and generates attachments between adjacent tissue surfaces. The presence of blood and post-operative bleeding increases the fibrin deposition. Most of the fibrin depositions will disperse by fibrinolysis. The fibrinous mass that will re‐ main, results in the organization and formation of adhesions [8]. Polymorphonuclear cells, macrophages, fibroblasts and mesothelial cells migrate and proliferate into the fibrinous exudate. Macrophages increase in number, change function and secrete a variety of substan‐ ces that recruit mesothelial cells onto the injured surfaces. Mesothelial cells form islands, proliferate and cover the injured area. All these cells release a variety of substances such as plasminogen activator, plasminogen activator inhibitor, arachidonic acid metabolites,reac‐ tive oxygen species, cytokines, IL-1, IL-6, tumor necrosis factor-a, prostaglandin E2, collage‐ nase, elastase and the transforming growth factors leukotriene B4 a and b(TGFa and TGFb). These factors modulate the process of peritoneal healing and adhesion formation [12-14]. The deposition is the key step for the healing process and the balance between deposition and degradation will determine normal peritoneal healing or adhesion formation. The fibrin absorption is controlled by fibrinolysis. The inactive plasminogen is converted to plasmin through tissue plasminogen activator (tPA) and urokinase type plasminogen activator (uPA). The tPA is present in both mesothelium and submesothelial blood vessels of serosal and peritoneal membranes[12,15]. The fibrinolytic activity normally begins three days after peritoneal injury and increases to a maximum by day 8. Therefore, those adhesions that will be formed are in place by day 8, when mesothelial regeneration has been completed [8]. Normal peritoneum has a high fibrolytic activity in order to prevent adhesion formation be‐ tween different tissue surfaces. During the inflammatory process, IL-1 and IL-6 stimulate epithelial and inflammatory cells to release plasminogen activator inhibitor 1 and 2 (PAI-1 and PAI-2), which inhibit fibrinolytic activity [16]. Patients with extensive adhesions have been found to have an overexpression of PAI-1 in the peritoneum [17]. Also, the deficient blood supply, the reduced tissue oxygenation and the release of reactive oxygen species that frequently co-exist with surgical trauma, decrease the peritoneal fibrinolytic activity [9,18].

### **3. Adhesion prevention**

gynecology represents the most innovative surgical approach, compared with laparotomy since it has been shown from a large number of clinical, but also experimental studies, that is associated with less development of *de novo* adhesions. Without any doubt, the most im‐ portant factor is the operating surgeon, whose attention to proper surgical technique will

The mechanism of adhesion formation represents a variation of the physiological healing process [8]. The process of peritoneal healing differs from that of other tissues. Peritoneal defects heal by a process of metaplasia from the underlying mesenchyme, partly from mi‐ gration of epithelial cells from the free peritoneal fluid and minimally through proliferation of epithelial cells from the defect's edges. Consequently, peritoneal wounds need the same time to heal regardless of their size, in contrast with other tissues, such as the skin, where large injuries take longer to heal than do small injuries [9]. There is no difference between peritoneal healing and adhesion formation for the first 3 days after peritoneal injury. Injuries to the peritoneum cause a disruption of stromal mast cells, resulting in the release of hista‐ mine and vasoactive cinins. Also as a response to trauma, various cytokines, such as inter‐ leukin (IL)-1, IL-6 and tumor necrosis factor-a (TNF-a) are locally released. The cytokines attract and activate macrophages to secrete vasodilating substances, which in turn, cause an increase in capillary permeability, leading to the formation of fibrous exudate [10]. Platelets are an important component of the inflammatory exudate and have the ability to adhere it to the traumatized surfaces. The platelet degranulation releases adrenaline, transforming growth factor b and serotonin and contribute to the production of prostaglandins and leuko‐ trienes. The chemokines direct the migration of cells to the injury site, while platelets con‐ tribute to the initial fibrin clot and to the initiation of the coagulation process [11]. The activation of the coagulation cascade leads to the transformation of the inactive prothrombin into thrombin that triggers the conversion of fibrinogen into monomers of fibrin, which in‐ teract and polymerize. The initially soluble polymer becomes insoluble by coagulation fac‐ tors such as factor XIIIa [12]. The exudate coagulates within 3 h and forms a fibrinous material that plugs the defective area and generates attachments between adjacent tissue surfaces. The presence of blood and post-operative bleeding increases the fibrin deposition. Most of the fibrin depositions will disperse by fibrinolysis. The fibrinous mass that will re‐ main, results in the organization and formation of adhesions [8]. Polymorphonuclear cells, macrophages, fibroblasts and mesothelial cells migrate and proliferate into the fibrinous exudate. Macrophages increase in number, change function and secrete a variety of substan‐ ces that recruit mesothelial cells onto the injured surfaces. Mesothelial cells form islands, proliferate and cover the injured area. All these cells release a variety of substances such as plasminogen activator, plasminogen activator inhibitor, arachidonic acid metabolites,reac‐ tive oxygen species, cytokines, IL-1, IL-6, tumor necrosis factor-a, prostaglandin E2, collage‐ nase, elastase and the transforming growth factors leukotriene B4 a and b(TGFa and TGFb). These factors modulate the process of peritoneal healing and adhesion formation [12-14].

serve as a mainstay for adhesion formation.

50 Endoscopy

**2. Mechanism of adhesion development**

In order to prevent the development and reformation of post-operative intra-abdominal adhe‐ sions a variety of surgical techniques and adjuvants have been proposed. Agents, that in theory can modify the mechanism of adhesion formation, have been evaluated in experimental trials and many of them have been advocated for use during surgery in humans. Surgical techniques are focused on the limitation of surgical trauma, prevention of ischaemia and exposure of peri‐ toneal cavity to foreign materials (Table 1). Improvement of surgical techniques can potentially reduce adhesion formation but cannot eliminate it. Anti-adhesive agents can be classified as pharmacological agents, systemic or intra-peritoneal, and intra-peritoneal barriers (solid or liquid). Pharmacological agents (Table 2) target the modification of inflammatory reaction (limitation of fibrin deposition), amplification of fibrin absorption and suppression of fibro‐ blast activity. Barriers (Table 3) are used in order to prevent traumatized peritoneal surface ap‐ position during the healing process so as to prevent tissue adherence [17,19].

```
Achieving excellent haemostasis and avoiding
local ischaemia
Avoiding foreign bodies (talc, starch)
Avoiding peritoneum suturing or use of fine
non-reactive suture
Minimizing surgical trauma
Minimizing tissue handling
Reducing drying or overheating of tissues
Reducing infection risk
Removing intra-peritoneal blood deposits
```
**Table 1.** Surgical techniques for prevention of adhesion formation


to a reduction in tissue oxygenation, anaerobic cell metabolism, acidosis and production of reactive oxygen species. The clinical impact of reactive oxygen species remains unclear but there is evidence that they are associated with increased adhesion formation [23]. Moreover it has been recently proposed that a low intra-peritoneal pressure (IPP) (8 mmHg) may be better than the standard IPP (12 mmHg) to minimize the adverse impact on the surgical per‐

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

53

Omental grafts Peritoneal grafts Bladder strips Fetal membranes Various oils Liquid paraffin Amniotic fluid Dextran

Crystalloid solutions Icodextrin 4% Polyglycan esters

polytetrafluoroethylene Oxidized regenerated

Fibrin, **N**,**O**carboxymethylchitosan

Silicone Vaseline Gelatin Metal foils Elastic and silk foils Expanded

cellulose Hyaluronic acid Carboxymethylcellulose Polyethylene glycol Polylactide

A wide variety of pharmacological agents (Table 2) have been used in attempts to prevent or attenuate the formation of post-surgical adhesions, but none of them has been found to be effective. The use of drugs for adhesion prevention has some obstacles that affect their effi‐ cacy. Ischaemia and inadequate blood supply are important factors in adhesion formation and these also decrease systemic drug delivery inhibiting their effectiveness. Peritoneum

itoneal environment during a CO2 pneumoperitoneum [24].

Solid barriers (membranes, gel) Endogenous tissue Fluid barriers Exogenous material

**Table 3.** Anti-adhesive barier methods.

**5. Pharmacological agents**

**Table 2.** Pharmacological anti-adhesive agents

### **4. Laparoscopy and adhesions**

The development of operative laparoscopy in gynaecology was associated with the expecta‐ tion of reduced adhesion formation. Therefore, a large number of experimental and human clinical trials has been performed, which have shown that, compared with laparotomy, lapa‐ roscopic surgery is associated with less development of adhesions [17,20,21]. Reduction of adhesion formation is facilitated by minimal tissue handling and trauma, avoidance of expo‐ sure to foreign bodies (powder from gloves, gauze particles, e.t.c.) and prevention of air pol‐ lution in the peritoneal cavity that leads to the reduction of tissue drying. Pneumoperitoneum via increased intra-abdominal pressure has a tamponade effect that fa‐ cilitates haemostasis, limits the use of diathermy and formation of ischaemic areas. In addi‐ tion, laparoscopy is associated with a lower incidence of post-operative infection [21,22]. On the other hand, it has been advocated that the beneficial effect of laparoscopy in adhesion formation might be reduced by the use of pneumoperitoneum with CO2 [12]. CO2 pneumo‐ peritoneum is associated with increased intra-abdominal pressure that compresses the splanchnic veins, reducing the blood flow by elevating vascular resistance. This stasis leads to a reduction in tissue oxygenation, anaerobic cell metabolism, acidosis and production of reactive oxygen species. The clinical impact of reactive oxygen species remains unclear but there is evidence that they are associated with increased adhesion formation [23]. Moreover it has been recently proposed that a low intra-peritoneal pressure (IPP) (8 mmHg) may be better than the standard IPP (12 mmHg) to minimize the adverse impact on the surgical per‐ itoneal environment during a CO2 pneumoperitoneum [24].


**Table 3.** Anti-adhesive barier methods.

Fibrinolytic agents Anticoagulants Anti-inflammatory

**Table 2.** Pharmacological anti-adhesive agents

**4. Laparoscopy and adhesions**

Fibrinolysin Papain

Urokinase Hyaluronidase

Elastase

Citrates Oxalates Heparin Corticosteroids Antihistamines

Tetracycline Cephalosporin Progesterone Oestrogens

Statins Melatonin

The development of operative laparoscopy in gynaecology was associated with the expecta‐ tion of reduced adhesion formation. Therefore, a large number of experimental and human clinical trials has been performed, which have shown that, compared with laparotomy, lapa‐ roscopic surgery is associated with less development of adhesions [17,20,21]. Reduction of adhesion formation is facilitated by minimal tissue handling and trauma, avoidance of expo‐ sure to foreign bodies (powder from gloves, gauze particles, e.t.c.) and prevention of air pol‐ lution in the peritoneal cavity that leads to the reduction of tissue drying. Pneumoperitoneum via increased intra-abdominal pressure has a tamponade effect that fa‐ cilitates haemostasis, limits the use of diathermy and formation of ischaemic areas. In addi‐ tion, laparoscopy is associated with a lower incidence of post-operative infection [21,22]. On the other hand, it has been advocated that the beneficial effect of laparoscopy in adhesion formation might be reduced by the use of pneumoperitoneum with CO2 [12]. CO2 pneumo‐ peritoneum is associated with increased intra-abdominal pressure that compresses the splanchnic veins, reducing the blood flow by elevating vascular resistance. This stasis leads

Antiproliferative agents Aromate inhibitors

Streptokinase, streptodornase

Chymotrypsin, trypsin, pepsin

Recombinant tissue plasminogen activator

Non-steroidal anti-inflammatory drugs

Gonadotrophin-releasing hormone agonists

agents Antibiotics Other agents

52 Endoscopy

### **5. Pharmacological agents**

A wide variety of pharmacological agents (Table 2) have been used in attempts to prevent or attenuate the formation of post-surgical adhesions, but none of them has been found to be effective. The use of drugs for adhesion prevention has some obstacles that affect their effi‐ cacy. Ischaemia and inadequate blood supply are important factors in adhesion formation and these also decrease systemic drug delivery inhibiting their effectiveness. Peritoneum has an extremely rapid absorption mechanism, that limits the half life and efficacy of many intra-peritoneally administered agents. Anti-adhesion agents must not affect normal wound healing, which has steps in common with adhesion formation (fibrinous exudate, fibrin dep‐ osition, fibroblast activity and proliferation) [19,25]. The clinical effectiveness of these agents has been evaluated in a systematic review and meta-analysis that analysed data from rele‐ vant randomized controlled trials (RCT) published up to 2005 [26].

**8. Progesterone and oestrogens**

**9. Anticoagulants – Fibrinolytics**

adhesion formation in animal models [42,43].

tion [38,39,40].

sion development [44].

Progesterone has been used for the prevention of post-operative adhesions. Administration of progesterone resulted in less adhesion formation in animal models, but does not appear to be effective in humans. Oestrogens have been associated with increased adhesion forma‐ tion in animal models. It was demonstrated that a hypo-oestrogenic state, produced by go‐ nadotrophin-releasing hormone agonists or aromatase inhibitors such as tamoxifen and anastrazole, decrease development of post-operative adhesions in experimental models

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

55

Anticoagulants such as heparin can reduce adhesion formation by inhibition of the coagu‐ lation cascade and promotion of fibrinolysis [36]. The use of heparin for intra-peritoneal irrigation in a dose that can reduce adhesion formation was associated with haemorrhage and delayed wound healing, but low-dose heparin irrigation showed no benefit in adhe‐ sion reduction [3,19,37]. In the only available RCT, heparin delivery with oxidized regen‐ erated cellulose failed to demonstrate a superior effect compared with oxidized regenerated cellulose alone [38]. Furthermore, in experimental trials, the combination of carboxymethylcellulose or 32% dextran 70 plus heparin failed to reduce adhesion forma‐

Fibrinolytic agents as streptokinase, elastase and tissue plasminogen activator produced by recombinant DNA techniques (rtPA) can contribute in adhesion prevention directly by re‐ ducing the fibrinous mass and indirectly by stimulating plasminogen activator activity. Sys‐ temic administration of anticoagulants is impeded by lack of safety. The concentrations of fibrinolytic agents required to prevent adhesion formation are too close to the anticoagulato‐ ry concentrations and increase the risk for post-operative haemorrhage and delayed wound healing. Intra-peritoneal administration is ineffective due to rapid absorption by the perito‐ neal membrane [3,25,41]. The use of carboxymethylcellulose gel and oxidized regenerated cellulose as a carrier to deliver rtPA intra-peritonealy was not associated with a reduction of

A recent study has investigated the impact of gonadotropin-releasing hormone analogue (GnRH-a) on coagulation and fibrinolytic activities and its effectiveness in the prevention of pelvic adhesion after myomectomy in thirty-two infertile women. Patients treated with GnRH-a showed significant decrease in plasminogen activator inhibitorPAI, thrombin acti‐ vatable fibrinolysis inhibitor (TAFI), factors V, and VIII and increased protein C (PC), but no significant change in plasminogen and α2-antiplasmin levels compared with control group, suggesting a possible critical role of the GnRH-a therapy in preventing postoperative adhe‐

[3,34,35]. This hypothesis, however, has never been tested in humans.

### **6. Non-steroidal anti-inflammatory drugs**

Non-steroidal anti-inflammatory drugs (NSAID) affect adhesion formation by several mech‐ anisms. They act by modifying arachidonic acid metabolism and altering cyclooxygenase ac‐ tivities. This results in decreased vascular permeability, platelet aggregation, and coagulation and enhanced macrophage function. A number of locally and systemically ad‐ ministered NSAID have been used in experimental trials.

No relevant clinical trials assessing the effectiveness of NSAID in adhesion prevention have been published to date in patients undergoing gynaecological surgery. Their clinical efficacy is questionable probably because of inadequate concentrations at the sites of surgical trauma or by rapid absorption from the peritoneal membrane [3,19,27].

### **7. Corticosteroids and antihistamines**

Corticosteroids alter the inflammatory response by reducing vascular permeability and de‐ creasing cytokine and chemotactic factor secretion. Antihistamines inhibit fibroblast prolif‐ eration and stabilize lysosomal membranes and histamine secretion. Corticosteroids have been used alone or plus antihistamines by intra-peritoneal or systemic administration or by flushing through Fallopian tubes post-operatively and were effective in many, but not all, experimental models. In the limited data from RCT [28,29,30], no significant beneficial effect was detected with the use of corticosteroids (systemic, intra-peritoneal or Fallopian tube flushing) in the deterioration of adhesion score at second-look laparoscopy or on the probability of clinical pregnancy. However, limited data suggest that the addition of postoperative steroids to systemic intra-operative steroids might be associated with a favoura‐ ble outcome both in terms of adhesion score deterioration (increase) or improvement (reduction) [31]. On the other hand, adverse events such as suppression of the pituitary– adrenal axis, immunosuppression and delayed wound healing have been reported with the use of corticosteroids [19,32,33]. Regarding antihistamines, only one RCT has evaluat‐ ed the role of oral promethazine in the prevention of adhesion formation after pelvic sur‐ gery. In that study, no significant difference was detected either in deterioration or improvement of adhesion score in patients who received promethazine as compared with those who did not [31].

### **8. Progesterone and oestrogens**

has an extremely rapid absorption mechanism, that limits the half life and efficacy of many intra-peritoneally administered agents. Anti-adhesion agents must not affect normal wound healing, which has steps in common with adhesion formation (fibrinous exudate, fibrin dep‐ osition, fibroblast activity and proliferation) [19,25]. The clinical effectiveness of these agents has been evaluated in a systematic review and meta-analysis that analysed data from rele‐

Non-steroidal anti-inflammatory drugs (NSAID) affect adhesion formation by several mech‐ anisms. They act by modifying arachidonic acid metabolism and altering cyclooxygenase ac‐ tivities. This results in decreased vascular permeability, platelet aggregation, and coagulation and enhanced macrophage function. A number of locally and systemically ad‐

No relevant clinical trials assessing the effectiveness of NSAID in adhesion prevention have been published to date in patients undergoing gynaecological surgery. Their clinical efficacy is questionable probably because of inadequate concentrations at the sites of surgical trauma

Corticosteroids alter the inflammatory response by reducing vascular permeability and de‐ creasing cytokine and chemotactic factor secretion. Antihistamines inhibit fibroblast prolif‐ eration and stabilize lysosomal membranes and histamine secretion. Corticosteroids have been used alone or plus antihistamines by intra-peritoneal or systemic administration or by flushing through Fallopian tubes post-operatively and were effective in many, but not all, experimental models. In the limited data from RCT [28,29,30], no significant beneficial effect was detected with the use of corticosteroids (systemic, intra-peritoneal or Fallopian tube flushing) in the deterioration of adhesion score at second-look laparoscopy or on the probability of clinical pregnancy. However, limited data suggest that the addition of postoperative steroids to systemic intra-operative steroids might be associated with a favoura‐ ble outcome both in terms of adhesion score deterioration (increase) or improvement (reduction) [31]. On the other hand, adverse events such as suppression of the pituitary– adrenal axis, immunosuppression and delayed wound healing have been reported with the use of corticosteroids [19,32,33]. Regarding antihistamines, only one RCT has evaluat‐ ed the role of oral promethazine in the prevention of adhesion formation after pelvic sur‐ gery. In that study, no significant difference was detected either in deterioration or improvement of adhesion score in patients who received promethazine as compared with

vant randomized controlled trials (RCT) published up to 2005 [26].

**6. Non-steroidal anti-inflammatory drugs**

54 Endoscopy

ministered NSAID have been used in experimental trials.

**7. Corticosteroids and antihistamines**

those who did not [31].

or by rapid absorption from the peritoneal membrane [3,19,27].

Progesterone has been used for the prevention of post-operative adhesions. Administration of progesterone resulted in less adhesion formation in animal models, but does not appear to be effective in humans. Oestrogens have been associated with increased adhesion forma‐ tion in animal models. It was demonstrated that a hypo-oestrogenic state, produced by go‐ nadotrophin-releasing hormone agonists or aromatase inhibitors such as tamoxifen and anastrazole, decrease development of post-operative adhesions in experimental models [3,34,35]. This hypothesis, however, has never been tested in humans.

### **9. Anticoagulants – Fibrinolytics**

Anticoagulants such as heparin can reduce adhesion formation by inhibition of the coagu‐ lation cascade and promotion of fibrinolysis [36]. The use of heparin for intra-peritoneal irrigation in a dose that can reduce adhesion formation was associated with haemorrhage and delayed wound healing, but low-dose heparin irrigation showed no benefit in adhe‐ sion reduction [3,19,37]. In the only available RCT, heparin delivery with oxidized regen‐ erated cellulose failed to demonstrate a superior effect compared with oxidized regenerated cellulose alone [38]. Furthermore, in experimental trials, the combination of carboxymethylcellulose or 32% dextran 70 plus heparin failed to reduce adhesion forma‐ tion [38,39,40].

Fibrinolytic agents as streptokinase, elastase and tissue plasminogen activator produced by recombinant DNA techniques (rtPA) can contribute in adhesion prevention directly by re‐ ducing the fibrinous mass and indirectly by stimulating plasminogen activator activity. Sys‐ temic administration of anticoagulants is impeded by lack of safety. The concentrations of fibrinolytic agents required to prevent adhesion formation are too close to the anticoagulato‐ ry concentrations and increase the risk for post-operative haemorrhage and delayed wound healing. Intra-peritoneal administration is ineffective due to rapid absorption by the perito‐ neal membrane [3,25,41]. The use of carboxymethylcellulose gel and oxidized regenerated cellulose as a carrier to deliver rtPA intra-peritonealy was not associated with a reduction of adhesion formation in animal models [42,43].

A recent study has investigated the impact of gonadotropin-releasing hormone analogue (GnRH-a) on coagulation and fibrinolytic activities and its effectiveness in the prevention of pelvic adhesion after myomectomy in thirty-two infertile women. Patients treated with GnRH-a showed significant decrease in plasminogen activator inhibitorPAI, thrombin acti‐ vatable fibrinolysis inhibitor (TAFI), factors V, and VIII and increased protein C (PC), but no significant change in plasminogen and α2-antiplasmin levels compared with control group, suggesting a possible critical role of the GnRH-a therapy in preventing postoperative adhe‐ sion development [44].

### **10. Antibiotics**

Antibiotics are commonly used for prophylaxis against post-operative infections and hence the inflammatory response that leads to adhesion formation. Peritoneal irrigation with anti‐ biotic solutions does not reduce adhesion formation, while it has been shown that in some cases it may promote them [45].

need suturing and are difficult to use via laparoscopic surgery. Their benefits are also limit‐ ed to the site of application and do not prevent the development of adhesions at sites of in‐ direct trauma. So the surgeon has to surmise where adhesions will be formed in order to choose the placement sites and optimize barrier efficacy [52]. Not infrequently, this proves to be a challenging task, since, for example, midline laparotomy initiates a generalized peri‐ toneal response that can lead to adhesion formation distant from surgical trauma [53].

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

57

Expanded polytetrafluoroethylene (Preclude, Gore-Tex Surgical Membrane; Johnson and

inhibits cellular migration and tissue adherence. In the only available RCT, it has been shown to be associated with fewer post-operative de-novo adhesions after myomectomy when compared with no treatment [54]. Moreover, when compared with oxidized regener‐ ated cellulose, Preclude was found to be more effective in terms of adhesion reformation af‐ ter adhesiolysis [55]. However, in another RCT, no evidence of a beneficial effect of Preclude was demonstrated in the de-novo formation of adhesions after laparoscopic myomectomy when compared to oxidized regenerated cellulose [56]. Expanded polytetrafluoroethylene has the disadvantages that it must be sutured in place, is difficult to use in laparoscopic sur‐ gery and, ideally, requires a subsequent surgical procedure for removal after the injury has healed [57]. The use of Preclude in Europe is limited and it has been withdrawn from the

Oxidized regenerated cellulose (Interceed (TC7); Johnson and Johnson) is the first degrada‐ ble barrier that was used in clinical practice and represents a modification of its precursor Surgicel, which has been used as a haemostatic agent for a long time. It is a mesh designed to be placed over or between traumatized surfaces. About 8 h after the application in the peritoneal cavity, it becomes a viscous gel and finally it is degraded to monosaccharides and completely absorbed in about 2 weeks [3,22]. Oxidized regenerated cellulose use in laparo‐ scopic surgery is feasible [8]. In order to evaluate the efficacy of oxidized regenerated cellu‐ lose in the prevention of the development of post-surgical adhesions, many studies have been carried out. A meta-analysis of 11 relevant RCT [51] has shown that the barrier is safe and reduces significantly the incidence of de-novo adhesions, as well as the reformation of adhesions as compared with no treatment in laparoscopy [58-62]. In laparotomy, the availa‐ ble RCT [63-68], when meta-analysed [51], demonstrated that a significant reduction in the reformation (or mixture) of adhesions can be expected with the use of oxidized regenerated cellulose as compared with the no treatment group. The product is site specific, thus the effi‐ cacy is limited to surgical situations where raw surfaces can be completely covered with the

Johnson, Arlington, TX) is a non-absorbable, non-reactive, synthetic material that

market in USA after the development of the absorbable barriers [25].

**14. Expanded polytetrafluoroethylene**

**15. Oxidized regenerated cellulose**

### **11. Other pharmacological regimens**

Many other agents, such as apoprotin, noxytioline, growth factor inhibitors and modulators, phosphatidylcholine, thiazolidinediones, colchicine and calcium channel blockers, have been utilized in experimental trials. The intra-peritoneal administration of noxytioline is the only one of these interventions that has been tested in the context of a RCT and no signifi‐ cant difference was identified in terms of reduction of adhesions and clinical pregnancy rates in patients who were administered intra-peritoneal noxytioline and the control group [29]. There is no data from RCT to support the conclusion that any of the other agents is effi‐ cacious in preventing the development of post-operative adhesions [19,46,47].

### **12. Anti-adhesive barriers**

The failure of pharmacological regimens to prevent adhesion formation has led to the reviv‐ al of the barrier technique. With the barrier technique, traumatized peritoneal surfaces are kept separated, during mesothelial regeneration, thus precluding adherence of adjacent or‐ gans and tissues and reducing the development of adhesions. The separation can be ach‐ ieved by the use of solid (films or gels) or fluid barriers [19,25]. Anti-adhesive barriers are currently the most useful adjuvant for prevention of post-operative adhesion formation. Nu‐ merous substances (Table 3) have been used as mechanical barriers to separate tissue surfa‐ ces. Most of these materials are of historical interest only and had no effect or even aggravated adhesion formation [48,49]. An anti-adhesive agent should be effective, safe, eco‐ nomical and easy to use in both open and laparoscopic surgery [50]. The clinical effective‐ ness of several of these agents has been evaluated in two recent Cochrane reviews [26,51].

### **13. Solid barriers**

Solid barriers are placed over one or between two traumatized surfaces providing a separa‐ tion that averts tissue apposition during the critical period of fibrin formation and mesothe‐ lial regeneration following surgical trauma. It should be noted though, that solid barriers have some significant drawbacks. They are often ineffective in the presence of blood, have a complex preparation and application, do not conform easily to the shape of pelvic organs, need suturing and are difficult to use via laparoscopic surgery. Their benefits are also limit‐ ed to the site of application and do not prevent the development of adhesions at sites of in‐ direct trauma. So the surgeon has to surmise where adhesions will be formed in order to choose the placement sites and optimize barrier efficacy [52]. Not infrequently, this proves to be a challenging task, since, for example, midline laparotomy initiates a generalized peri‐ toneal response that can lead to adhesion formation distant from surgical trauma [53].

### **14. Expanded polytetrafluoroethylene**

**10. Antibiotics**

56 Endoscopy

cases it may promote them [45].

**12. Anti-adhesive barriers**

**13. Solid barriers**

**11. Other pharmacological regimens**

Antibiotics are commonly used for prophylaxis against post-operative infections and hence the inflammatory response that leads to adhesion formation. Peritoneal irrigation with anti‐ biotic solutions does not reduce adhesion formation, while it has been shown that in some

Many other agents, such as apoprotin, noxytioline, growth factor inhibitors and modulators, phosphatidylcholine, thiazolidinediones, colchicine and calcium channel blockers, have been utilized in experimental trials. The intra-peritoneal administration of noxytioline is the only one of these interventions that has been tested in the context of a RCT and no signifi‐ cant difference was identified in terms of reduction of adhesions and clinical pregnancy rates in patients who were administered intra-peritoneal noxytioline and the control group [29]. There is no data from RCT to support the conclusion that any of the other agents is effi‐

The failure of pharmacological regimens to prevent adhesion formation has led to the reviv‐ al of the barrier technique. With the barrier technique, traumatized peritoneal surfaces are kept separated, during mesothelial regeneration, thus precluding adherence of adjacent or‐ gans and tissues and reducing the development of adhesions. The separation can be ach‐ ieved by the use of solid (films or gels) or fluid barriers [19,25]. Anti-adhesive barriers are currently the most useful adjuvant for prevention of post-operative adhesion formation. Nu‐ merous substances (Table 3) have been used as mechanical barriers to separate tissue surfa‐ ces. Most of these materials are of historical interest only and had no effect or even aggravated adhesion formation [48,49]. An anti-adhesive agent should be effective, safe, eco‐ nomical and easy to use in both open and laparoscopic surgery [50]. The clinical effective‐ ness of several of these agents has been evaluated in two recent Cochrane reviews [26,51].

Solid barriers are placed over one or between two traumatized surfaces providing a separa‐ tion that averts tissue apposition during the critical period of fibrin formation and mesothe‐ lial regeneration following surgical trauma. It should be noted though, that solid barriers have some significant drawbacks. They are often ineffective in the presence of blood, have a complex preparation and application, do not conform easily to the shape of pelvic organs,

cacious in preventing the development of post-operative adhesions [19,46,47].

Expanded polytetrafluoroethylene (Preclude, Gore-Tex Surgical Membrane; Johnson and Johnson, Arlington, TX) is a non-absorbable, non-reactive, synthetic material that

inhibits cellular migration and tissue adherence. In the only available RCT, it has been shown to be associated with fewer post-operative de-novo adhesions after myomectomy when compared with no treatment [54]. Moreover, when compared with oxidized regener‐ ated cellulose, Preclude was found to be more effective in terms of adhesion reformation af‐ ter adhesiolysis [55]. However, in another RCT, no evidence of a beneficial effect of Preclude was demonstrated in the de-novo formation of adhesions after laparoscopic myomectomy when compared to oxidized regenerated cellulose [56]. Expanded polytetrafluoroethylene has the disadvantages that it must be sutured in place, is difficult to use in laparoscopic sur‐ gery and, ideally, requires a subsequent surgical procedure for removal after the injury has healed [57]. The use of Preclude in Europe is limited and it has been withdrawn from the market in USA after the development of the absorbable barriers [25].

### **15. Oxidized regenerated cellulose**

Oxidized regenerated cellulose (Interceed (TC7); Johnson and Johnson) is the first degrada‐ ble barrier that was used in clinical practice and represents a modification of its precursor Surgicel, which has been used as a haemostatic agent for a long time. It is a mesh designed to be placed over or between traumatized surfaces. About 8 h after the application in the peritoneal cavity, it becomes a viscous gel and finally it is degraded to monosaccharides and completely absorbed in about 2 weeks [3,22]. Oxidized regenerated cellulose use in laparo‐ scopic surgery is feasible [8]. In order to evaluate the efficacy of oxidized regenerated cellu‐ lose in the prevention of the development of post-surgical adhesions, many studies have been carried out. A meta-analysis of 11 relevant RCT [51] has shown that the barrier is safe and reduces significantly the incidence of de-novo adhesions, as well as the reformation of adhesions as compared with no treatment in laparoscopy [58-62]. In laparotomy, the availa‐ ble RCT [63-68], when meta-analysed [51], demonstrated that a significant reduction in the reformation (or mixture) of adhesions can be expected with the use of oxidized regenerated cellulose as compared with the no treatment group. The product is site specific, thus the effi‐ cacy is limited to surgical situations where raw surfaces can be completely covered with the mesh and its benefit is limited to the site of barrier placement. The fundamental disadvant‐ age is that it becomes ineffective when the entire area is not completely haemostatic. The presence of small amounts of blood in the peritoneal cavity or post-operative bleeding re‐ sults in blood permeating the mesh, fibrin deposition and, finally, adhesion formation [8,69,70]. In addition, as reported previously, the combination of oxidized regenerated cellu‐ lose plus heparin resulted in a significant reduction of adhesion formation and reformation in experimental models. This improvement in efficacy was not confirmed in clinical trials [36,38,40]. Oxidized regenerated cellulose has been approved by the US Food and Drink Ad‐ ministration (FDA) for use in open surgery in the USA [69].

from indirect trauma and finally before the end of the procedures [3,77,78]. In a blind, pro‐ spective, randomized, placebo-controlled multicentre study, where patients had undergone open gynecological procedures, low-viscosity 0.04% HA resulted in a statistically significant reduction of adhesions, as well as of the mean adhesion score, at second-look laparoscopy. However, it was not effective in reducing post-operative adhesion formation at sites of di‐ rect surgical trauma [78]. It has been approved by the FDA for use in open surgery in the USA [22]. HA cross-linked to HA (Hyalobarrier Gel; Baxter, Bracknell, UK) is a site-specific highly viscous gel is considered as easy to use in laparoscopic and open surgery. In a pro‐ spective, randomized, controlled study where the rate of post-surgical adhesions after lapa‐ roscopic myomectomy was examined, cross-linked HA resulted in significantly more adhesion-free patients [79]. Pregnancy rates at 6 and 12 months after laparoscopic myomec‐ tomy were significantly higher in patients treated with cross-linked HA [80]. In another randomized trial, adhesion-free patients after laparoscopic myomectomy were greater in the treatment group but the difference was not statistically significant. The incidence and severi‐ ty of adhesions was similar in both groups, but a significant reduction of uterine adhesions was found in the treatment group [81]. When the data from the two aforementioned studies were combined, a statistically significant reduction of adhesions during second-look laparo‐ scopy was detected in the group of patients treated with HA-cross-linked HA as compared with the control group. Auto-cross-linked internal ester form of HA (ACP gel; Fidia Ad‐ vanced Biopolymers, AbanoTerme, Italy) has the biocompatibility of the original polymer but higher viscosity and extended residence. It is a gel that has been shown to be efficacious in reducing abdominal adhesions in experimental models [82,83]. Two prospective random‐ ized controlled trials have been published so far by the same group regarding the use of ACP gel for the prevention of intrauterine adhesions after hysteroscopic surgery. In these studies, ACP gel has been associated with a significant reduction in the incidence and the severity of subsequent intrauterine adhesions [84,85]. A stratified analysis of these two stud‐ ies confirmed this finding by demonstrating a significant reduction in the proportion of pa‐ tients with adhesions at second-look hysteroscopy. Cross-linked thiol-modified HA with 4% polyethyleneglycoldiacrylate (Carbylan-S and Carbylan-SX; CarbylanBioSurgery, Palo Alto, CA, USA) is a bioabsorbable solution of HA. Carbylan-S is a hydrogel and Carbylan-SX has two formats, a sprayable gel and a hydrogel film. In animal models, Carbylan- S containing mitomycin C and Carbylan-SX were effective in prevention of post-operative intra-abdomi‐

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

59

Polylactide (copolymer of 70:30 poly(L-lactide-CO-D, L-lactide; SurgiWrap, MacroporeBio‐ surgeryinc., San Diego, USA) is a bioabsorbable film with a long absorption period (up to 6 months). It is metabolized to lactic acid and finally to CO2 and exhaled through the respira‐ tory system. It requires suturing in order to avoid its loss from the site. In preclinical studies, polylactide appears to be effective in the reduction of adhesion formation, but there are no

data currently for safety and efficacy in humans [87,88].

nal adhesions [52,86].

**17. Polylactide**

### **16. Hyaluronic acid**

Hyaluronic acid (HA) is a linear polysaccharide with repeating disaccharide units that are composed of sodium D-glucuronate and N-acetyl-D-glucosamine. It is a naturally occurring component of many body tissues and fluids, where it provides mechanically protective and physically supportive roles [69]. Various combinations of HA have been used for the pre‐ vention of adhesion formation. HA and carboxymethylcellulose (Seprafilm; Genzyme, Cam‐ bridge, Massachusetts, USA) is an absorbable membrane that dissolves and forms a hydrophilic gel approximately 24 h after placement. It is a site-specific barrier and acts by separating mechanically opposite tissue surfaces and lasts for 7 days. The HA is completely cleared from the body within 4 weeks, but the absorption of carboxymethylcellulose is not well known. It does not conform to the shape of pelvic organs as well as oxidized regenerat‐ ed cellulose and is usually used to prevent adhesions between the incision of anterior ab‐ dominal wall and bowel or omentum [71,72]. Its use in laparoscopic procedures is difficult. In a blind prospective, randomized, multicentre study, the treatment of patients after myo‐ mectomy with Seprafilm significantly reduced the extent and area of post-operative uterine adhesions [72]. Potential side effects include induced foreign body reaction, higher incidence of pulmonary emboli and intra-peritoneal abscess formation, but these findings were not statistically significant in the relevant trials [3,73]. High cost is another limitation because, for an effective protection from intestinal obstruction, a mean of 4.5 sheets per patient is re‐ quired [25]. Seprafilm has been approved by the FDA for use in open surgery in the USA [22]. Ferric hyaluronate 0.5% gel (Intergel; Gynecare, Sommerville, New Jersey, USA) is a viscous gel that provides a broader coverage than previous site-specific agents. It was shown to be easy to use in open and laparoscopic surgery. In relevant prospective random‐ ized trials, ferric hyaluronate was associated with a significant reduction of severity and ex‐ tent of post-operative adhesions and statistically significant improvement of the American Fertility Society (AFS) and modified AFS scores at second-look laparoscopy [69,74,75]. It was withdrawn from the market in 2003 because of problems with late onset post-operative pain and rare reports of sclerosing peritonitis [25,76]. Low-viscosity 0.04% HA combined with phosphate-buffered saline (Sepracoat; Genzyme) is a bioabsorbable macromolecular dilute solution of HA that is cleared from the body in less than 5 days. The solution is applied in the peritoneal cavity before any tissue manipulation in order to protect peritoneal surfaces from indirect trauma and finally before the end of the procedures [3,77,78]. In a blind, pro‐ spective, randomized, placebo-controlled multicentre study, where patients had undergone open gynecological procedures, low-viscosity 0.04% HA resulted in a statistically significant reduction of adhesions, as well as of the mean adhesion score, at second-look laparoscopy. However, it was not effective in reducing post-operative adhesion formation at sites of di‐ rect surgical trauma [78]. It has been approved by the FDA for use in open surgery in the USA [22]. HA cross-linked to HA (Hyalobarrier Gel; Baxter, Bracknell, UK) is a site-specific highly viscous gel is considered as easy to use in laparoscopic and open surgery. In a pro‐ spective, randomized, controlled study where the rate of post-surgical adhesions after lapa‐ roscopic myomectomy was examined, cross-linked HA resulted in significantly more adhesion-free patients [79]. Pregnancy rates at 6 and 12 months after laparoscopic myomec‐ tomy were significantly higher in patients treated with cross-linked HA [80]. In another randomized trial, adhesion-free patients after laparoscopic myomectomy were greater in the treatment group but the difference was not statistically significant. The incidence and severi‐ ty of adhesions was similar in both groups, but a significant reduction of uterine adhesions was found in the treatment group [81]. When the data from the two aforementioned studies were combined, a statistically significant reduction of adhesions during second-look laparo‐ scopy was detected in the group of patients treated with HA-cross-linked HA as compared with the control group. Auto-cross-linked internal ester form of HA (ACP gel; Fidia Ad‐ vanced Biopolymers, AbanoTerme, Italy) has the biocompatibility of the original polymer but higher viscosity and extended residence. It is a gel that has been shown to be efficacious in reducing abdominal adhesions in experimental models [82,83]. Two prospective random‐ ized controlled trials have been published so far by the same group regarding the use of ACP gel for the prevention of intrauterine adhesions after hysteroscopic surgery. In these studies, ACP gel has been associated with a significant reduction in the incidence and the severity of subsequent intrauterine adhesions [84,85]. A stratified analysis of these two stud‐ ies confirmed this finding by demonstrating a significant reduction in the proportion of pa‐ tients with adhesions at second-look hysteroscopy. Cross-linked thiol-modified HA with 4% polyethyleneglycoldiacrylate (Carbylan-S and Carbylan-SX; CarbylanBioSurgery, Palo Alto, CA, USA) is a bioabsorbable solution of HA. Carbylan-S is a hydrogel and Carbylan-SX has two formats, a sprayable gel and a hydrogel film. In animal models, Carbylan- S containing mitomycin C and Carbylan-SX were effective in prevention of post-operative intra-abdomi‐ nal adhesions [52,86].

### **17. Polylactide**

mesh and its benefit is limited to the site of barrier placement. The fundamental disadvant‐ age is that it becomes ineffective when the entire area is not completely haemostatic. The presence of small amounts of blood in the peritoneal cavity or post-operative bleeding re‐ sults in blood permeating the mesh, fibrin deposition and, finally, adhesion formation [8,69,70]. In addition, as reported previously, the combination of oxidized regenerated cellu‐ lose plus heparin resulted in a significant reduction of adhesion formation and reformation in experimental models. This improvement in efficacy was not confirmed in clinical trials [36,38,40]. Oxidized regenerated cellulose has been approved by the US Food and Drink Ad‐

Hyaluronic acid (HA) is a linear polysaccharide with repeating disaccharide units that are composed of sodium D-glucuronate and N-acetyl-D-glucosamine. It is a naturally occurring component of many body tissues and fluids, where it provides mechanically protective and physically supportive roles [69]. Various combinations of HA have been used for the pre‐ vention of adhesion formation. HA and carboxymethylcellulose (Seprafilm; Genzyme, Cam‐ bridge, Massachusetts, USA) is an absorbable membrane that dissolves and forms a hydrophilic gel approximately 24 h after placement. It is a site-specific barrier and acts by separating mechanically opposite tissue surfaces and lasts for 7 days. The HA is completely cleared from the body within 4 weeks, but the absorption of carboxymethylcellulose is not well known. It does not conform to the shape of pelvic organs as well as oxidized regenerat‐ ed cellulose and is usually used to prevent adhesions between the incision of anterior ab‐ dominal wall and bowel or omentum [71,72]. Its use in laparoscopic procedures is difficult. In a blind prospective, randomized, multicentre study, the treatment of patients after myo‐ mectomy with Seprafilm significantly reduced the extent and area of post-operative uterine adhesions [72]. Potential side effects include induced foreign body reaction, higher incidence of pulmonary emboli and intra-peritoneal abscess formation, but these findings were not statistically significant in the relevant trials [3,73]. High cost is another limitation because, for an effective protection from intestinal obstruction, a mean of 4.5 sheets per patient is re‐ quired [25]. Seprafilm has been approved by the FDA for use in open surgery in the USA [22]. Ferric hyaluronate 0.5% gel (Intergel; Gynecare, Sommerville, New Jersey, USA) is a viscous gel that provides a broader coverage than previous site-specific agents. It was shown to be easy to use in open and laparoscopic surgery. In relevant prospective random‐ ized trials, ferric hyaluronate was associated with a significant reduction of severity and ex‐ tent of post-operative adhesions and statistically significant improvement of the American Fertility Society (AFS) and modified AFS scores at second-look laparoscopy [69,74,75]. It was withdrawn from the market in 2003 because of problems with late onset post-operative pain and rare reports of sclerosing peritonitis [25,76]. Low-viscosity 0.04% HA combined with phosphate-buffered saline (Sepracoat; Genzyme) is a bioabsorbable macromolecular dilute solution of HA that is cleared from the body in less than 5 days. The solution is applied in the peritoneal cavity before any tissue manipulation in order to protect peritoneal surfaces

ministration (FDA) for use in open surgery in the USA [69].

**16. Hyaluronic acid**

58 Endoscopy

Polylactide (copolymer of 70:30 poly(L-lactide-CO-D, L-lactide; SurgiWrap, MacroporeBio‐ surgeryinc., San Diego, USA) is a bioabsorbable film with a long absorption period (up to 6 months). It is metabolized to lactic acid and finally to CO2 and exhaled through the respira‐ tory system. It requires suturing in order to avoid its loss from the site. In preclinical studies, polylactide appears to be effective in the reduction of adhesion formation, but there are no data currently for safety and efficacy in humans [87,88].

### **18. Polyethylene glycol**

Polyethylene glycol (SprayGel; Confluent Surgical, Waltham, Massachusetts, USA). It is a syn‐ thetic hydrogel formed when two polyethylene glycol-based liquids are sprayed together with an air assisted sprayer at the target tissue, where they cross-link and form a hydrogel barrier. One liquid is clear and one is coloured with methylene blue in order that facilitate its application. The gel remains intact for approximately 5–7 days and then gradually breaks down by hydroly‐ sis and is cleared through the kidneys [89]. Drawbacks of the product are the intricacy of prepa‐ ration and application, the time required to cover the target tissue and the high cost. In a prospective randomized controlled phase-III trial, in 40 patients undergoing myomectomy, pol‐ ylactide resulted in a significant decrease in the mean tenacity score. The extent of adhesions was increased in the control group but the difference was not significant. Also, the proportion of ad‐ hesion-free patients at second-look laparoscopy was increased in the treatment group but the difference was not statistically significant [89]. It has been approved for use in laparoscopic and open surgery in Europe, but by the FDA only for use in open surgery in USA [22,25].

[92]. Obviously, the use of human blood products raises a theoretical risk for transmission of infectious diseases. According to the pathogenesis of adhesions, application of fibrin glue at the traumatized peritoneal surfaces should increase adhesion formation. Possibly, fibrin glue application confines fibrin deposition and averts the development of attachments be‐ tween opposing tissue surfaces. In animal studies, the use of fibrin glue has been shown to decrease adhesion formation and reformation but clinical data are limited. Fibrin glue has not been approved by the FDA for use in USA [22,47]. So far, no relevant data from trials in

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

61

**N,O**-carboxymethylchitosan (Adhes-X, Chitogenics, New Jersey, USA) is a purified deriva‐ tive of chitin obtained from the exoskeleton of shrimp and has similar structure to hyaluron‐ ic acid and carboxymethylcellulose [93]. The product comprises both a clear gel and a solution. The gel is placed initially at the sites of surgical trauma where it is tamped with a laparoscopic instrument and subsequently the solution is placed at the same places. Its effi‐ cacy and safety have been confirmed in some animal models. A prospective randomized controlled study, performed on 34 patients undergoing laparoscopy for various gynaecolog‐ ical indications, demonstrated a decrease in the recurrence, extent and severity of adhesions and a decrease of de-novo adhesion formation at second-look laparoscopy, but none of these

Fluids constitute an ideal barrier agent because their action is not limited to the site of applica‐ tion. Their function is provided by hydrofloration of intra-peritoneal structures in the liquid that is infused into the peritoneal cavity at the end of the surgical procedure. Hydrofloration provides a temporary separation between raw peritoneal surfaces allowing independent heal‐ ing without the formation of adhesions. Possibly, fluid circulation in the peritoneal cavity con‐ tributes to the prevention of adhesion formation by diluting fibrinous exudates released from traumatized surfaces. Fluid barriers may prevent adhesion formation both at the traumatized area and elsewhere in the pelvis. The instillation of fluids in the peritoneal cavity may be associ‐ ated with some undesirable side effects, such as leakage from the incision, labial oedema, feel‐ ing of fluid moving around, abdominal discomfort, abdominal distension and complications such as pulmonary and peripheral oedema. Large volumes of intra-peritoneal fluids may de‐

Crystalloid solutions (Ringer's lactate, NaCl 0.9%) are rapidly absorbed by the peritoneal cavity, at a rate of 30–50 ml/h. Consequently, 24 h after the surgery, minimal or no crystal‐

crease the peritoneum ability to confront bacterial infections [3,17,76].

humans have been published.

**21. Carboxymethylchitosan**

findings were statistically significant [94].

**22. Fluid barriers**

**23. Crystalloid solutions**

### **19. Carboxymethylcellulose**

Carboxymethylcellulose is a high-molecular-weight polysaccharide, derivative of cellulose. The mechanism of its absorption is not well known. It has been used in combination with rtPA and with HA. A composite gel of carboxymethylcellulose and polyethylene oxide (Oxiplex; FzioMed, San Luis Obispo, CA, USA) is a viscoelastic gel, which acts as a barrier between tissues that inhibits protein deposition and thrombus formation [74]. The gel is absorbed by 6 weeks, but in cases where large amounts of gel were applied in multiple layers to the surgically treated sites or in cases of stage-IV endometriosis, small collections of gelatinous material were noted in areas of gel application or in areas deep in the cul-de-sac [90]. In two blind randomized control‐ led trials, where patients underwent adnexal surgery, carboxymethylcellulose and polyethy‐ lene oxide showed a significant improvement of AFS score in the treated group, but not in all clinical situations. It did not appear to provide this benefit to patients with grade-IV endometrio‐ sis [74,91]. Another double-blind prospective randomized controlled trial has shown that the mean AFS score for patients in the treatment group was unchanged, while in control patients an increased AFS score was noted [91]. No statistical pooling was feasible for these three studies, since the data were not analysed and presented per randomization unit (they were analysed per adnexa and not per patient). It is easy to use in laparoscopic surgery and it has been approved in Europe for use in abdominal and pelvic surgery [25].

### **20. Fibrin glue**

Fibrin glue (Tissucol; Baxter International, Deerfield, IL, USA) is a biological product. Fibrin glue is made by mixing human fibrinogen with bovine thrombin, calcium and factor XIII [92]. Obviously, the use of human blood products raises a theoretical risk for transmission of infectious diseases. According to the pathogenesis of adhesions, application of fibrin glue at the traumatized peritoneal surfaces should increase adhesion formation. Possibly, fibrin glue application confines fibrin deposition and averts the development of attachments be‐ tween opposing tissue surfaces. In animal studies, the use of fibrin glue has been shown to decrease adhesion formation and reformation but clinical data are limited. Fibrin glue has not been approved by the FDA for use in USA [22,47]. So far, no relevant data from trials in humans have been published.

### **21. Carboxymethylchitosan**

**18. Polyethylene glycol**

60 Endoscopy

**19. Carboxymethylcellulose**

Europe for use in abdominal and pelvic surgery [25].

**20. Fibrin glue**

Polyethylene glycol (SprayGel; Confluent Surgical, Waltham, Massachusetts, USA). It is a syn‐ thetic hydrogel formed when two polyethylene glycol-based liquids are sprayed together with an air assisted sprayer at the target tissue, where they cross-link and form a hydrogel barrier. One liquid is clear and one is coloured with methylene blue in order that facilitate its application. The gel remains intact for approximately 5–7 days and then gradually breaks down by hydroly‐ sis and is cleared through the kidneys [89]. Drawbacks of the product are the intricacy of prepa‐ ration and application, the time required to cover the target tissue and the high cost. In a prospective randomized controlled phase-III trial, in 40 patients undergoing myomectomy, pol‐ ylactide resulted in a significant decrease in the mean tenacity score. The extent of adhesions was increased in the control group but the difference was not significant. Also, the proportion of ad‐ hesion-free patients at second-look laparoscopy was increased in the treatment group but the difference was not statistically significant [89]. It has been approved for use in laparoscopic and

open surgery in Europe, but by the FDA only for use in open surgery in USA [22,25].

Carboxymethylcellulose is a high-molecular-weight polysaccharide, derivative of cellulose. The mechanism of its absorption is not well known. It has been used in combination with rtPA and with HA. A composite gel of carboxymethylcellulose and polyethylene oxide (Oxiplex; FzioMed, San Luis Obispo, CA, USA) is a viscoelastic gel, which acts as a barrier between tissues that inhibits protein deposition and thrombus formation [74]. The gel is absorbed by 6 weeks, but in cases where large amounts of gel were applied in multiple layers to the surgically treated sites or in cases of stage-IV endometriosis, small collections of gelatinous material were noted in areas of gel application or in areas deep in the cul-de-sac [90]. In two blind randomized control‐ led trials, where patients underwent adnexal surgery, carboxymethylcellulose and polyethy‐ lene oxide showed a significant improvement of AFS score in the treated group, but not in all clinical situations. It did not appear to provide this benefit to patients with grade-IV endometrio‐ sis [74,91]. Another double-blind prospective randomized controlled trial has shown that the mean AFS score for patients in the treatment group was unchanged, while in control patients an increased AFS score was noted [91]. No statistical pooling was feasible for these three studies, since the data were not analysed and presented per randomization unit (they were analysed per adnexa and not per patient). It is easy to use in laparoscopic surgery and it has been approved in

Fibrin glue (Tissucol; Baxter International, Deerfield, IL, USA) is a biological product. Fibrin glue is made by mixing human fibrinogen with bovine thrombin, calcium and factor XIII **N,O**-carboxymethylchitosan (Adhes-X, Chitogenics, New Jersey, USA) is a purified deriva‐ tive of chitin obtained from the exoskeleton of shrimp and has similar structure to hyaluron‐ ic acid and carboxymethylcellulose [93]. The product comprises both a clear gel and a solution. The gel is placed initially at the sites of surgical trauma where it is tamped with a laparoscopic instrument and subsequently the solution is placed at the same places. Its effi‐ cacy and safety have been confirmed in some animal models. A prospective randomized controlled study, performed on 34 patients undergoing laparoscopy for various gynaecolog‐ ical indications, demonstrated a decrease in the recurrence, extent and severity of adhesions and a decrease of de-novo adhesion formation at second-look laparoscopy, but none of these findings were statistically significant [94].

### **22. Fluid barriers**

Fluids constitute an ideal barrier agent because their action is not limited to the site of applica‐ tion. Their function is provided by hydrofloration of intra-peritoneal structures in the liquid that is infused into the peritoneal cavity at the end of the surgical procedure. Hydrofloration provides a temporary separation between raw peritoneal surfaces allowing independent heal‐ ing without the formation of adhesions. Possibly, fluid circulation in the peritoneal cavity con‐ tributes to the prevention of adhesion formation by diluting fibrinous exudates released from traumatized surfaces. Fluid barriers may prevent adhesion formation both at the traumatized area and elsewhere in the pelvis. The instillation of fluids in the peritoneal cavity may be associ‐ ated with some undesirable side effects, such as leakage from the incision, labial oedema, feel‐ ing of fluid moving around, abdominal discomfort, abdominal distension and complications such as pulmonary and peripheral oedema. Large volumes of intra-peritoneal fluids may de‐ crease the peritoneum ability to confront bacterial infections [3,17,76].

### **23. Crystalloid solutions**

Crystalloid solutions (Ringer's lactate, NaCl 0.9%) are rapidly absorbed by the peritoneal cavity, at a rate of 30–50 ml/h. Consequently, 24 h after the surgery, minimal or no crystal‐ loid solution would be left in the peritoneal cavity. The instillation of crystalloids does not seem to result in decreased adhesion formation. They are commonly used but they are not approved for use as anti-adhesive agents [25,69,95]. Crystalloids have also been used in vari‐ ous combinations with heparin, steroids, antihistamines and other pharmacological agents in randomized controlled trials, but none of them has been found effective in decreasing post-operative adhesion formation or improving pregnancy rates [96].

reduction of incidence, severity and extent of adhesions but these results were not statistical‐ ly significant [104]. However, recently, in the largest prospective randomized double-blind multicentre study for an anti-adhesive agent, icodextrin 4% has been shown to result in a significant reduction of incidence, severity and extent of adhesions and a significant im‐ provement of AFS score. Also the study showed that icodextrin 4% prevents the deteriora‐ tion of pre-existing adhesions, considering that patients with the higher number of adhesion lysed at initial surgery had the greater reduction in adhesion incidence [95]. A stratified analysis of these two studies revealed a statistically significant effect oficodextrin 4% use on the de-novo formation of adhesions, as well as on the proportion of patients with an im‐ provement of the adhesion score at second-look laparoscopy [105]. Simultaneously with clinical trials, a European patients registry (ARIEL) was created allowing surgeons to record and report the experiences of the use of icodextrin 4% in open and laparoscopic gynaecolog‐ ical and general surgery. The registry provides feedback on routine use in 4620 patients (2882 that underwent gynaecological and 1738 general surgery). The general consensus is that it is easy to use in both open and laparoscopic surgery, it is well tolerated by patients and the incidence of adverse events is considered similar to the control group [76,106]. Low cost is another advantage of icodextrin 4%. Adept (1.5 litre bags) are about half the price of each sheet of Interceed or Seprafilm and it is about four times cheaper than one SprayGel package [50]. Icodextrin 4% has been approved for use in open and laparoscopic surgery in Europe and it was the first anti-adhesive agent that has been approved by the FDA for use

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

63

Development of post-operative adhesion is a widespread consequence of surgical trauma and healing following open or laparoscopic gynecological surgery and is associated with significant complications. At present, the main strategy to avoid formation and reformation of adhesions is focused on the use of careful surgical techniques and anti-adhesive agents. Reduction of adhesion formation after laparoscopic surgery in comparison to the more con‐ ventional approach by laparotomy can be attributed to less tissue manipulation, less tissue drying, avoidance of insertion of foreign bodies such as talc from the surgical gloves, fibers from the gauzes e.t.c. On the other hand pneumoperitoneum during laparoscopy exerts a tamponade effect that facilitates hemostasis, so minimizing the use of electrocautery, which is known that leads to the formation of ischaemic areas and therefore predisposing to adhe‐ sion formation. The use of CO2 for pnemoperitoneum may lead to adhesion formation, since its use is associated with reduction in tissue oxygenation, acidosis and release ofreactive oxygen species, which are considered adhesiogenic. Therefore, the addition of oxygen, the heating of the insufflatedCO2 or the alternative use of other gases (i.e. helium) may be bene‐ ficial in terms of reduction of *de novo* adhesion formation. At the end of each operation an «underwater» examination should be used in order to document complete intra-peritoneal hemostasis, since it has been clearly demonstrated that incomplete hemostasis is associated

in laparoscopic surgery in the USA [25,76,91,95].

**27. Conclusions**

with adhesion formation.

### **24. Dextran**

Dextran (32% dextran 70; Hyskon; Pharmacia, Piscataway, New Jersey, USA) is a 1–6-linked dextrose polymer. A summary [26] of the available data from relevant RCT [37,97-99] dem‐ onstrated a decreased proportion of patients with adhesions at second-look laparoscopy in the group that received 32% dextran 70, as compared with the group that did not. However, despite the fact that the patients with improvement and deterioration in the adhesion score at second-look laparoscopy were increased and decreased, respectively, in the treatment group, when compared with the control group, this difference was not statistically signifi‐ cant. In addition, its use was associated with significant side effects as pulmonary and pe‐ ripheral oedema caused by its osmotic properties, liver function abnormalities, pleural effusion and, rarely, allergic reactions or anaphylactic shock and disseminated intra-vascu‐ lar coagulation. It has not been approved for use as an anti-adhesive agent [3,17,100,101].

### **25. Polyglycan esters**

Polyglycanesters (Adcon-P; Gliatech, Cleveland, Ohio) is a viscous bioabsorbable solution. Its prototypes Adcon-L and Adcon-T/N were found effective for adhesion prevention in spi‐ nal and neurosurgical procedures. Experimental studies have shown that application of Ad‐ con-P effectively reduces development of post-operative intra-abdominal adhesions. There are no data for the safety and the efficacy of this product in humans [102].

### **26. Icodextrin**

Icodextrin 4% (Adept; Shire Pharmaceuticals, Basingstoke, Hampshire, UK) is a 1–4-linked glucose polymer. Icodextrin 4% is a clear isomolar solution and does not predispose to infec‐ tion. It is absorbed gradually via the lymphatic system into the systemic circulation, where it is digested to oligosaccharides by amylase. Amylase is absent from the human peritoneal cavity. Preclinical studies had shown significant reduction of post-operative adhesions and confirmed the safety of icodextrin 4%. It was indicated that the agent was more effective in adhesion reduction when used as both an irrigant and post-operative instillate [103]. In a small double-blind prospective randomized multicentre study, icodextrin 4% resulted in the reduction of incidence, severity and extent of adhesions but these results were not statistical‐ ly significant [104]. However, recently, in the largest prospective randomized double-blind multicentre study for an anti-adhesive agent, icodextrin 4% has been shown to result in a significant reduction of incidence, severity and extent of adhesions and a significant im‐ provement of AFS score. Also the study showed that icodextrin 4% prevents the deteriora‐ tion of pre-existing adhesions, considering that patients with the higher number of adhesion lysed at initial surgery had the greater reduction in adhesion incidence [95]. A stratified analysis of these two studies revealed a statistically significant effect oficodextrin 4% use on the de-novo formation of adhesions, as well as on the proportion of patients with an im‐ provement of the adhesion score at second-look laparoscopy [105]. Simultaneously with clinical trials, a European patients registry (ARIEL) was created allowing surgeons to record and report the experiences of the use of icodextrin 4% in open and laparoscopic gynaecolog‐ ical and general surgery. The registry provides feedback on routine use in 4620 patients (2882 that underwent gynaecological and 1738 general surgery). The general consensus is that it is easy to use in both open and laparoscopic surgery, it is well tolerated by patients and the incidence of adverse events is considered similar to the control group [76,106]. Low cost is another advantage of icodextrin 4%. Adept (1.5 litre bags) are about half the price of each sheet of Interceed or Seprafilm and it is about four times cheaper than one SprayGel package [50]. Icodextrin 4% has been approved for use in open and laparoscopic surgery in Europe and it was the first anti-adhesive agent that has been approved by the FDA for use in laparoscopic surgery in the USA [25,76,91,95].

### **27. Conclusions**

loid solution would be left in the peritoneal cavity. The instillation of crystalloids does not seem to result in decreased adhesion formation. They are commonly used but they are not approved for use as anti-adhesive agents [25,69,95]. Crystalloids have also been used in vari‐ ous combinations with heparin, steroids, antihistamines and other pharmacological agents in randomized controlled trials, but none of them has been found effective in decreasing

Dextran (32% dextran 70; Hyskon; Pharmacia, Piscataway, New Jersey, USA) is a 1–6-linked dextrose polymer. A summary [26] of the available data from relevant RCT [37,97-99] dem‐ onstrated a decreased proportion of patients with adhesions at second-look laparoscopy in the group that received 32% dextran 70, as compared with the group that did not. However, despite the fact that the patients with improvement and deterioration in the adhesion score at second-look laparoscopy were increased and decreased, respectively, in the treatment group, when compared with the control group, this difference was not statistically signifi‐ cant. In addition, its use was associated with significant side effects as pulmonary and pe‐ ripheral oedema caused by its osmotic properties, liver function abnormalities, pleural effusion and, rarely, allergic reactions or anaphylactic shock and disseminated intra-vascu‐ lar coagulation. It has not been approved for use as an anti-adhesive agent [3,17,100,101].

Polyglycanesters (Adcon-P; Gliatech, Cleveland, Ohio) is a viscous bioabsorbable solution. Its prototypes Adcon-L and Adcon-T/N were found effective for adhesion prevention in spi‐ nal and neurosurgical procedures. Experimental studies have shown that application of Ad‐ con-P effectively reduces development of post-operative intra-abdominal adhesions. There

Icodextrin 4% (Adept; Shire Pharmaceuticals, Basingstoke, Hampshire, UK) is a 1–4-linked glucose polymer. Icodextrin 4% is a clear isomolar solution and does not predispose to infec‐ tion. It is absorbed gradually via the lymphatic system into the systemic circulation, where it is digested to oligosaccharides by amylase. Amylase is absent from the human peritoneal cavity. Preclinical studies had shown significant reduction of post-operative adhesions and confirmed the safety of icodextrin 4%. It was indicated that the agent was more effective in adhesion reduction when used as both an irrigant and post-operative instillate [103]. In a small double-blind prospective randomized multicentre study, icodextrin 4% resulted in the

are no data for the safety and the efficacy of this product in humans [102].

post-operative adhesion formation or improving pregnancy rates [96].

**24. Dextran**

62 Endoscopy

**25. Polyglycan esters**

**26. Icodextrin**

Development of post-operative adhesion is a widespread consequence of surgical trauma and healing following open or laparoscopic gynecological surgery and is associated with significant complications. At present, the main strategy to avoid formation and reformation of adhesions is focused on the use of careful surgical techniques and anti-adhesive agents. Reduction of adhesion formation after laparoscopic surgery in comparison to the more con‐ ventional approach by laparotomy can be attributed to less tissue manipulation, less tissue drying, avoidance of insertion of foreign bodies such as talc from the surgical gloves, fibers from the gauzes e.t.c. On the other hand pneumoperitoneum during laparoscopy exerts a tamponade effect that facilitates hemostasis, so minimizing the use of electrocautery, which is known that leads to the formation of ischaemic areas and therefore predisposing to adhe‐ sion formation. The use of CO2 for pnemoperitoneum may lead to adhesion formation, since its use is associated with reduction in tissue oxygenation, acidosis and release ofreactive oxygen species, which are considered adhesiogenic. Therefore, the addition of oxygen, the heating of the insufflatedCO2 or the alternative use of other gases (i.e. helium) may be bene‐ ficial in terms of reduction of *de novo* adhesion formation. At the end of each operation an «underwater» examination should be used in order to document complete intra-peritoneal hemostasis, since it has been clearly demonstrated that incomplete hemostasis is associated with adhesion formation.

Finally, several anti-adhesive agents are used during laparoscopic intrventions, in order to minimizepostoperative adhesions. These fall into two main categories, which include phar‐ macological agents and barrier methods. Limited data support the use of the former, either locally or systemically. Barriers, which mechanically separate the opposed serosal surfaces and exert their beneficial action, at least partly, because they remain in place beyond the crit‐ ical 3-day point, at which competition of fibrinolytic activityandfibrosis will lead to adhe‐ sion formation. The tissue separation can be achieved either by the use of solid (films or gel) or fluid barriers. The clinical effectiveness of several of these agents has been thoroughly evaluated in two recent Cochrane reviews by Metwally et al [26] and Ahmad et al [51].

[9] DiZerega, G.S. Biochemical events in peritoneal tissue repair. Eur. J. Surg. Suppl.

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

65

[10] Badia, J.M., Whawell, S.A., Scott-Coombes, D.M., Abel, P.D., Williamson, R.C., Thompson, J.N. Peritoneal and systemic cytokine response to laparotomy. Br. J. Surg.

[11] Boland, G.M., Weigel, R.J. Formation and prevention of postoperative abdominal ad‐

[12] Binda, M.M., Molinas, C.R., Koninckx, P.R. Reactive oxygen species and adhesion formation: clinical implications in adhesion prevention. Hum. Reprod. 2003; 18:

[13] Drollette, C.M., Badawy, S.Z. Pathophysiology of pelvic adhesions. Modern trends in

[14] Rodgers, K.E., diZerega, G.S. Function of peritoneal exudate cells after abdominal

[15] Dano, K., Andreasen, P.A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L.S., Skriver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res. 1985; 44:

[16] Buckman, R.F., Woods, M., Sargent, L., Gervin, A.S. A unifying pathogenetic mecha‐ nism in the etiology of intraperitoneal adhesions. J. Surg. Res. 1976; 20: 1–5. [17] Sutton, C. Adhesions and their prevention. Obstet. Gynaecol. 2005; 7: 168–176.

[18] Raftery, A.T. Effect of peritoneal trauma on peritoneal fibrinolytic activity and intra‐ peritoneal adhesion formation. An experimental study in the rat. Eur. Surg. Res.

[20] Lundorff, P., Hahlin, M., Kallfelt, B., Thorburn, J., Lindblom, B. Adhesion formation after laparoscopic surgery in tubal pregnancy: a randomized trial versus laparotomy.

[21] Schafer, M., Krahenb hl, L., Buchler, M.W. Comparison of adhesion formation in

[22] The Practice Committee of the ASRM. Control and prevention of peritoneal adhe‐

[23] de Souza, A.M., Wang, C.C., Chu, C.Y., Lam, P.M., Rogers, M.S. The effect of intraabdominal pressure on the generation of 8-iso prostaglandin F2alpha during laparo‐

[24] Matsuzaki S, Jardon K, Maleysson E, D'Arpiani F, Canis M, Botchorishvili R. Impact of intraperitoneal pressure of a CO2 pneumoperitoneum on the surgical peritoneal

[19] Risberg, B. Adhesions: preventive strategies. Eur. J. Surg. Suppl. 1997;32: 39.

open and laparoscopic surgery. Dig. Surg. 1998; 15: 148–152.

sions in gynecologic surgery. Fertil. Steril. 2006;86: S1–S5.

scopy in rabbits. Hum. Reprod. 2003;18: 2181–2188.

environment. Hum Reprod. 2012;27(6): 1613-23.

preventing infertility. J. Reprod. Med. 1992; 37: 107–121.

1997; 10: 16.

2503–2507.

139–266.

1981;13:397–401.

Fertil. Steril. 1991;55: 911–915.

1996;83: 347–348.

hesions. J. Surg. Res. 2006; 132: 3–12.

surgery. J. Invest. Surg. 1993; 6: 9–23.

### **Author details**

George Pados, Anastasios Makedos and Basil Tarlatzis

1st Dept. of OB-GYN, School of Medicine, Aristotle University of Thessaloniki, «Papageor‐ giou» General Hospital, N. Efkarpia, Greece

### **References**


[9] DiZerega, G.S. Biochemical events in peritoneal tissue repair. Eur. J. Surg. Suppl. 1997; 10: 16.

Finally, several anti-adhesive agents are used during laparoscopic intrventions, in order to minimizepostoperative adhesions. These fall into two main categories, which include phar‐ macological agents and barrier methods. Limited data support the use of the former, either locally or systemically. Barriers, which mechanically separate the opposed serosal surfaces and exert their beneficial action, at least partly, because they remain in place beyond the crit‐ ical 3-day point, at which competition of fibrinolytic activityandfibrosis will lead to adhe‐ sion formation. The tissue separation can be achieved either by the use of solid (films or gel) or fluid barriers. The clinical effectiveness of several of these agents has been thoroughly evaluated in two recent Cochrane reviews by Metwally et al [26] and Ahmad et al [51].

1st Dept. of OB-GYN, School of Medicine, Aristotle University of Thessaloniki, «Papageor‐

[1] Holmdahl, L., Risberg, B., Beck, D.E., et al. Adhesions: pathogenesis and prevention-

[2] Menzies, D., Ellis, H. Intestinal obstruction from adhesions – how big is the problem?

[3] Liakakos, T., Thomakos, N., Fine, P.M., Dervenis, C., Young, R.L. Peritoneal adhe‐ sions: etiology, pathophysiology, and clinical significance. Recent advances in pre‐

[4] Menzies, D. Peritoneal adhesions. Incidence, cause, and prevention. Surg. Annu.

[5] Operative Laparoscopy Study Group. Postoperative adhesion development after op‐ erative laparoscopy: evaluation at early second-look procedures. Fertil. Steril. 1991;

[6] Lower, A.M., Hawthorn, R.J., Clark, D., et al. Adhesion- related readmissions follow‐ ing gynaecological laparoscopy or laparotomy in Scotland: an epidemiological study

[7] Diamond, M.P., Freeman, M.L. Clinical implications of postsurgical adhesions. Hum.

[8] Pados, G.A., Devroey, P. Adhesions. Curr. Opin. Obstet. Gynecol. 1992; 4: 412–418.

panel discussion and summary. Eur. J. Surg. Suppl. 1997; 56: 62.

vention and management.Dig. Surg. 2001; 18: 260–273.

of 24 046 patients. Hum. Reprod. 2004;19: 1877–1885.

Reprod. Update. 2001; 7: 567–576.

**Author details**

64 Endoscopy

**References**

1992; 24: 27–45.

55: 700–704.

George Pados, Anastasios Makedos and Basil Tarlatzis

Ann. R. Coll. Surg. Engl. 1992; 72: 60–63.

giou» General Hospital, N. Efkarpia, Greece


[25] Trew, G: Postoperative adhesions and their prevention. Rev. Gynaecol. Perinat. Pract. 2006;6: 47–56.

[39] Diamond, M.P., Linsky, C.B., Cunningham, T., et al. Synergistic effects of INTER‐ CEED(TC7) and heparin in reducing adhesion formation in the rabbit uterine horn

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

67

[40] Reid, R.L., Lie, K., Spence, J.E., Tulandi, T., Yuzpe, A. Clinical evaluation of the effi‐ cacy of heparin-saturated Interceed for prevention of adhesion reformation in the

[41] Doody, K.J., Dunn, R.C., Buttram Jr., V.C. Recombinant tissue plasminogen activator reduces adhesion formation in a rabbit uterine horn model. Fertil. Steril. 1989;51:

[42] Bothin, C. Counteracting postsurgical adhesions – the effect of combining oxidized regenerated cellulose and tissue plasminogen activator. Int. J. Fertil. Menopausal

[43] Gehlbach, D.L., O'Hair, K.C., Parks, A.L., Rosa, C. Combined effects of tissue plasmi‐ nogen activator and carboxymethylcellulose on adhesion reformation in rabbits. Int.

[44] Di Nardo MA, Annunziata ML, Ammirabile M, Di Minno MN, Ruocco AL, De Falco M, Di Lieto A.Pelvic adhesion and gonadotropin-releasing hormone analogue: effects of triptorelin acetate depot on coagulation and fibrinolytic activities. Reprod Sci.

[45] Rappaport, W.D., Holcomb, M., Valente, J., Chvapil, M. Antibiotic irrigation and the

[46] Demirturk, F., Aytan, H., Caliskan, A., et al. The effect of rosiglitazone in the preven‐ tion of intra-abdominal adhesion formation in a rat uterine horn model. Hum. Re‐

[47] Hellebrekers, B.W., Trimbos-Kemper, G.C., van Blitterswijk, C.A., Bakkum, E.A., Trimbos, J.B. Effects of five different barrier materials on postsurgical adhesion for‐

[48] Arora, M., Jaroudi, K.A., Hamilton, C.J., Dayel, F. Controlled comparison of intercede and amniotic membrane graft in the prevention of postoperative adhesions in the rabbit uterine horn model. Eur. J. Obstet. Gynecol. Reprod. Biol. 1994;55: 179–182.

[49] Seifer, D.B., Diamond, M.P., DeCherney, A.H. An appraisal of barrier agents in the reduction of adhesion formation following surgery. J. Gynecol. Surg. 1990; 6: 3–10.

[50] Trew, G., Lower, A. Consensus in adhesion reduction management. Obstetr. Gynae‐

[51] Ahmad, G., Duffy, J.M., Farquhar, C., et al. Barrier agentsfor adhesion prevention af‐ ter gynaecological surgery. Cochrane Database Syst Rev, CD000475, 2008.

formation of intraabdominal adhesions. Am. J. Surg. 1989;158: 435–437.

pelvic sidewall of the human. Prog. Clin. Biol. Res. 1993;381: 261–264.

model. Fertil. Steril. 1991;55(b): 389–394.

J. Fertil. Menopausal Stud. 1994;39: 172–176.

mation in the rat. Hum. Reprod. 2000;15: 1358–1363.

509–512.

Stud. 1995;40: 102–105.

2012;19(6):615-22.

col. 2004; 6: 1–2.

prod. 2006;21: 3008–3013,.


[39] Diamond, M.P., Linsky, C.B., Cunningham, T., et al. Synergistic effects of INTER‐ CEED(TC7) and heparin in reducing adhesion formation in the rabbit uterine horn model. Fertil. Steril. 1991;55(b): 389–394.

[25] Trew, G: Postoperative adhesions and their prevention. Rev. Gynaecol. Perinat.

[26] Metwally, M., Watson, A., Lilford, R., Vandekerckhove, P. Fluid and pharmacologi‐ cal agents for adhesion prevention after gynaecological surgery. Cochrane Database

[27] Luciano, A.A., Hauser, K.S., Benda, J. Evaluation of commonly used adjuvants in the prevention of postoperative adhesions. Am. J. Obstet. Gynecol. 1983;146: 88–92.

[28] Jansen, R.P. Failure of intraperitoneal adjuncts to improve the outcome of pelvic op‐

[29] Querleu, D., Vankeerberghen-Deffense, F., Boutteville, C. The effect of noxytioline and systemic corticosteroids in infertility surgery. A prospective randomized study. (Traitement adjuvant des plastiestubaires. Etude prospective randomisee des cortico‐ ides par voiegeneraleet de la noxytioline). J. Gynecol. Obstet. Biol. Reprod. 1989;18:

[30] Rock, J.A., Siegler, A.M., Meisel, M.B. The efficacy of postoperative hydrotubation: a randomized prospective multicenter clinical trial. Fertil. Steril. 1984;42(2): 373–376.

[31] Jansen, R.P. Controlled clinical approaches to investigating the prevention of perito‐

[32] Granat, M., Schenker, J.G., Mor-Yosef, S., Rosenkovitch, E., Castellanos, R.C., Galili, U. Effects of dexamethasone on proliferation of autologous fibroblasts and on the im‐ mune profile in women undergoing pelvic surgery for infertility. Fertil. Steril.

[33] Harris, W.J., Daniell, J.F: Use of corticosteroids as an adjuvant in terminal salpingos‐

[34] Kaya, U., Oktem, M., Zeyneloglu, H.B., Ozen, O., Kuscu, E. Impact of aromatase in‐ hibitors on adhesion formation in a rat model. Fertil. Steril. 2007;87: 934–939.

[35] Montanino-Oliva, M., Metzger, D.A., Luciano, A.A. Use of medroxyprogesterone acetate in the prevention of postoperative adhesions. Fertil. Steril. 1996;65: 650–654.

[36] Diamond, M.P., Linsky, C.B., Cunningham, T. Adhesion reformation: reduction by

[37] Jansen, R.P.Failure of peritoneal irrigation with heparin during pelvic operations upon young women to reduce adhesions. Surg. Gynecol. Obstet. 1988;166: 154–160.

[38] Reid, R.L., Hahn, P.M., Spence, J.E., Tulandi, T., Yuzpe, A.A., Wiseman, D.M. A randomized clinical trial of oxidized regenerated cellulose adhesion barrier (Inter‐

ceed, TC7) alone or in combination with heparin. Fertil. Steril.1997; 67: 23–29.

the use of Interceed (TC7) plus heparin. J. Gynecol. Surg. 1991;7(a): 1–6.

neal adhesions. Prog. Clin. Biol. Res. 1990;358: 177–192.

erations in young women. Am. J. Obstet. Gynecol. 1985;153: 363–371.

Pract. 2006;6: 47–56.

66 Endoscopy

935–940.

1983;39: 180–186.

tomy. Fertil. Steril. 1983;40: 785–789.

Syst Rev, CD001298, 2006.


[52] Liu, Y., Li, H., Shu, X.Z., Gray, S.D., Prestwich, G.D. Crosslinkedhyaluronan hydro‐ gels containing mitomycin C reduce postoperative abdominal adhesions. Fertil. Ster‐ il. (Suppl. 1). 2005; 83:1275–1283.

[64] Franklin, R.R. Reduction of ovarian adhesions by the use of Interceed. Ovarian Adhe‐

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

69

[65] Li, T.C., Cooke, I.D. The value of an absorbable adhesion barrier, Interceed, in the prevention of adhesion reformation following microsurgical adhesiolysis. Br. J. Ob‐

[66] Nordic APSG. The efficacy of Interceed(TC7)\* for prevention of reformation of post‐ operative adhesions on ovaries, fallopian tubes, and fimbriae in microsurgical opera‐ tions for fertility: a multicenter study. Nordic Adhesion Prevention Study Group.

[67] Sekiba, K. Use of Interceed(TC7) absorbable adhesion barrier to reduce postoperative adhesion reformation in infertility and endometriosis surgery. The Obstetrics and Gynecology Adhesion Prevention Committee. Obstet. Gynecol. 1992;79: 518–522.

[68] Van Geldorp, H. Interceed absorbable adhesion barrier reduces the formation of postsurgical adhesions after ovarian surgery. Fertil. Steril. 1994;273: 213–214.

[69] Johns, D.B., Keyport, G.M., Hoehler, F., diZerega, G.S. Reduction of postsurgical ad‐ hesions with Intergel adhesion prevention solution: a multicenter study of safety and

efficacy after conservative gynecologic surgery. Fertil. Steril. 2001;76: 595–604.

view of 13 clinical studies. J. Reprod. Med. 1996;41: 27–34.

Seprafilm Adhesion Study Group. Fertil. Steril. 1996;66: 904–910.

surgery by laparoscopy in Europe. Hum. Reprod. 2005;20: 514–520.

port of a case. Dis. Colon Rectum 1999;42: 1639–1643.

[70] Larsson, B. Efficacy of Interceed in adhesion prevention in gynecologic surgery: a re‐

[71] Beck, D.E. The role of Seprafilmbioresorbable membrane in adhesion prevention.

[72] Diamond, M.P.Reduction of adhesions after uterine myomectomy by Seprafilm membrane (HAL-F): a blinded, prospective, randomized, multicenter clinical study.

[73] Klingler, P.J., Floch, N.R., Seelig, M.H., Branton, S.A., Wolfe, J.T., Metzger, P.P. Se‐ prafilm-induced peritoneal inflammation: a previously unknown complication. Re‐

[74] Lundorff, P., Donnez, J., Korell, M., Audebert, A.J., Block, K., diZerega, G.S. Clinical evaluation of a viscoelastic gel for reduction of adhesions following gynaecological

[75] Thornton, M.H., Johns, D.B., Campeau, J.D., Hoehler, F., DiZerega, G.S. Clinical eval‐ uation of 0.5% ferric hyaluronate adhesion prevention gel for the reduction of adhe‐ sions following peritoneal cavity surgery: open-label pilot study. Hum. Reprod.

[76] Sutton, C., Minelli, L., Garcıa, E., et al.Use of icodextrin 4% solution in the reduction of adhesion formation after gynaecological surgery. Gynecol. Surg. 2005;2: 287–296.

sion Study Group. Obstet. Gynecol. 1995;86: 335–340.

stet. Gynaecol. 1994;101: 335–339.

Fertil. Steril. 1995;63: 709–714.

Eur. J. Surg. Suppl. 1997;49: 55.

1998;13: 1480–1485.


[64] Franklin, R.R. Reduction of ovarian adhesions by the use of Interceed. Ovarian Adhe‐ sion Study Group. Obstet. Gynecol. 1995;86: 335–340.

[52] Liu, Y., Li, H., Shu, X.Z., Gray, S.D., Prestwich, G.D. Crosslinkedhyaluronan hydro‐ gels containing mitomycin C reduce postoperative abdominal adhesions. Fertil. Ster‐

[53] Becker, J.M., Stucchi, A.F.Intra-abdominal adhesion prevention: are we getting any

[54] Myomectomy ASG. An expanded polytetrafluoroethylene barrier (Gore-Tex Surgical Membrane) reduces post-myomectomy adhesion formation. The Myomectomy Ad‐

[55] Haney, A.F., Hesla, J., Hurst, B.S., et al. Expanded polytetrafluoroethylene (Gore-Tex Surgical Membrane) is superior to oxidized regenerated cellulose (Interceed TC7+) in

[56] Korell, M. Reduction of adhesion by INTERCEED Barrier and Gortex Surgical Mem‐ brane after laparoscopic myomectomy, Moglichkeiten der Adhasionprophylaxe, Mu‐

[57] Farquhar, C., Vandekerckhove, P., Watson, A., Vail, A., Wiseman, D: Barrier agents for preventing adhesions after surgery for subfertility. Cochrane Database Syst Rev,

[58] Keckstein, J., Ulrich, U., Sasse, V., Roth, A., Tuttlies, F., Karageorgieva, E. Reduction of postoperative adhesion formation after laparoscopic ovarian cystectomy. Hum.

[59] Mais, V., Ajossa, S., Marongiu, D., Peiretti, R.F., Guerriero, S., Melis, G.B. Reduction of adhesion reformation after laparoscopic endometriosis surgery: a randomized trial with an oxidized regenerated cellulose absorbable barrier. Obstet. Gynecol.

[60] Mais, V., Ajossa, S., Piras, B., Guerriero, S., Marongiu, D., Melis, G.B. Prevention of de-novo adhesion formation after laparoscopic myomectomy: a randomized trial to evaluate the effectiveness of an oxidized regenerated cellulose absorbable barrier.

[61] Saravelos, H., Li, T.C. Post-operative adhesions after laparoscopic electrosurgical treatment for polycystic ovarian syndrome with the application of Interceed to one ovary: a prospective randomized controlled study. Hum. Reprod. 1996;11: 992–997.

[62] Wallwiener, D., Meyer, A., Bastert, G. Adhesion formation of the parietal and viscer‐ al peritoneum: an explanation for the controversy on the use of autologous and allo‐

[63] Azziz, R. Microsurgery alone or with INTERCEED Absorbable Adhesion Barrier for pelvic sidewall adhesion re-formation. The INTERCEED (TC7) Adhesion Barrier

hesion Multicenter Study Group. Fertil. Steril. 1995;63: 491–493.

preventing adhesions. Fertil. Steril. 1995;63: 1021–1026.

il. (Suppl. 1). 2005; 83:1275–1283.

nich, 1994.

68 Endoscopy

CD000475, 2000.

Reprod. 1996;11: 579–582.

Hum. Reprod. 1995;10(b): 3133–3135.

plastic barriers? Fertil. Steril. 1998;69: 132–137.

Study Group II. Surg. Gynecol. Obstet. 1993;177: 135–139.

1995;86(a): 512–515.

closer? Ann. Surg. 2004;240: 202–204.


[77] Burns, J.W., Skinner, K., Colt, J., et al. Prevention of tissue injury and postsurgical ad‐ hesions by precoating tissues with hyaluronic acid solutions. J. Surg. Res. 1995;59: 644–652.

[89] Mettler, L., Audebert, A., Lehmann-Willenbrock, E., Schive-Peterhansl, K., Jacobs, V.R. A randomized, prospective, controlled, multicenter clinical trial of a sprayable, site-specific adhesion barrier system in patients undergoing myomectomy. Fertil.

Adhesion Prevention Strategies in Laparoscopic Surgery

http://dx.doi.org/10.5772/52694

71

[90] Young, P., Johns, A., Templeman, C., et al. Reduction of postoperative adhesions af‐ ter laparoscopic gynecological surgery with Oxiplex/AP Gel: a pilot study. Fertil.

[91] diZerega, G.S., Verco, S.J., Young, P., et al. A randomized, controlled pilot study of the safety and efficacy of 4% icodextrin solution in the reduction of adhesions follow‐

[92] Evrard, V.A., De Bellis, A., Boeckx, W., Brosens, I.A. Peritoneal healing after fibrin glue application: a comparative study in a rat model. Hum. Reprod. 1996;11: 1877–

[93] Krause, T.J., Zazanis, G.A., McKinnon, R.D. Prevention of postoperative adhesions with the chitin derivative N–O–carboxymethylchitosan. Wound Repair Regen.

[94] Diamond, M.P., Luciano, A., Johns, D.A., Dunn, R., Young, P., Bieber, E. Reduction of postoperative adhesions by N, O-carboxymethylchitosan: a pilot study. Fertil. Steril.

[95] Brown, C.B., Luciano, A.A., Martin, D., Peers, E., Scrimgeour, A., diZerega, G.S. Adept (icodextrin 4% solution) reduces adhesions after laparoscopic surgery for ad‐ hesiolysis: a double- blind, randomized, controlled study. Fertil. Steril. 2007;88: 1413–

[96] Wiseman, D.M., Trout, J.R., Franklin, R.R., Diamond, M.P. Meta-analysis of the safety and efficacy of an adhesion barrier (Interceed TC7) in laparotomy. J. Reprod. Med.

[97] Adhesion Study Group. Reduction of postoperative pelvic adhesions with intraperi‐ toneal 32% dextran 70: a prospective, randomized clinical trial. Fertil. Steril. 1983;40:

[98] Larsson, B., Lalos, O., Marsk, L., et al.Effect of intraperitoneal instillation of 32% dex‐ tran 70 on postoperative adhesion formation after tubal surgery. Acta Obstet. Gyne‐

[99] Rosenberg, S.M., Board, J.A. High-molecular weight dextran in human infertility sur‐

[100] Ricaurte, E., Hilgers, T.W. Safety of intraperitoneal 32% dextran 70 as an antiadhe‐

ing laparoscopic gynaecological surgery. Hum. Reprod. 2002;17: 1031–1038.

Steril. 2004;82: 398–404.

Steril. 2005; 84: 1450–1456.

1880.

1426.

612–619.

1996;4: 53–57.

2003;80: 631–636.

1999;44: 325–331.

col. Scand. 1985;64: 437–441.

gery. Am. J. Obstet. Gynecol. 1984;148: 380–385.

sion adjuvant. J. Reprod. Med. 1989;34: 535–539.


[89] Mettler, L., Audebert, A., Lehmann-Willenbrock, E., Schive-Peterhansl, K., Jacobs, V.R. A randomized, prospective, controlled, multicenter clinical trial of a sprayable, site-specific adhesion barrier system in patients undergoing myomectomy. Fertil. Steril. 2004;82: 398–404.

[77] Burns, J.W., Skinner, K., Colt, J., et al. Prevention of tissue injury and postsurgical ad‐ hesions by precoating tissues with hyaluronic acid solutions. J. Surg. Res. 1995;59:

[78] Diamond, M.P. Reduction of de novo postsurgical adhesions by intraoperative pre‐ coating with Sepracoat (HAL-C) solution: a prospective, randomized, blinded, place‐ bo-controlled multicenter study. The Sepracoat Adhesion Study Group. Fertil. Steril.

[79] Pellicano, M., Bramante, S., Cirillo, D., et al. Effectiveness of autocrosslinked hyalur‐ onic acid gel after laparoscopic myomectomy in infertile patients: a prospective,

[80] Pellicano, M., Guida, M., Bramante, S., et al: Reproductive outcome after autocros‐ slinked hyaluronic acid gel application in infertile patients who underwent laparo‐

[81] Mais, V., Bracco, G.L., Litta, P., Gargiulo, T., Melis, G.B. Reduction of postoperative adhesions with an auto-crosslinkedhyaluronan gel in gynaecological laparoscopic surgery: a blinded, controlled, randomized, multicentre study. Hum. Reprod.

[82] Belluco, C., Meggiolaro, F., Pressato, D., et al. Prevention of postsurgical adhesions with an autocrosslinkedhyaluronan derivative gel. J. Surg. Res. 2001;100: 217- 221.

[83] De Iaco, P.A., Stefanetti, M., Pressato, D., et al. A novel hyaluronan-based gel in lapa‐ roscopic adhesion prevention: preclinical evaluation in an animal model. Fertil. Ster‐

[84] Acunzo, G., Guida, M., Pellicano, M., et al. Effectiveness of auto-cross-linked hyalur‐ onic acid gel in the prevention of intrauterine adhesions after hysteroscopicadhesiol‐ ysis: a prospective, randomized, controlled study. Hum. Reprod. 2003;18: 1918–1921.

[85] Guida, M., Acunzo, G., Di SpiezioSardo, A., et al. Effectiveness of auto-crosslinked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic surgery: a prospective, randomized, controlled study. Hum. Reprod. 2004;19:1461–

[86] Liu, Y., Shu, X.Z., Prestwich, G.D. Reduced postoperative intra-abdominal adhesions using Carbylan-SX, a semisynthetic glycosaminoglycan hydrogel. Fertil. Steril.

[87] Zong, X., Li, S., Chen, E., et al. Prevention of postsurgery- induced abdominal adhe‐ sions by electrospunbioabsorbablenanofibrouspoly(lactide-co-glycolide)-based mem‐

[88] Avital, S., Bollinger, T.J., Wilkinson, J.D., Marchetti, F., Hellinger, M.D., Sands, L.R. Preventing intra-abdominal adhesions with polylactic acid film: an animal study.

randomized, controlled study. Fertil. Steril. 2003;80: 441–444.

scopic myomectomy. Fertil. Steril. 2005;83: 498–500.

644–652.

70 Endoscopy

1998;69: 1067–1074.

2006;21: 1248–1254.

il. 1998;69: 318– 323.

1464.

2007;87: 940–948.

branes. Ann. Surg. 2004;240: 910–915.

Dis. Colon Rectum 2005;48: 153–157.


[101] Watson, A., Vandekerckhove, P., Lilford, R. Pharmacological adjuvants during infer‐ tility surgery: a systematic review of evidence derived from randomized controlled trials. Hum. Fertil. 1999; 2: 149–157.

**Section 2**

**Head and Neck**


**Section 2**
